PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.68%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-2.25%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-16.28%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.24%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-14.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.50%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-13.75%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.46%
Share reduction while AVGO is at 0.36%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.88%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.31%
Dividend reduction while AVGO stands at 4.79%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-61.75%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-66.59%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
42.07%
10Y revenue/share CAGR under 50% of AVGO's 271.80%. Michael Burry would suspect a lasting competitive disadvantage.
2.81%
5Y revenue/share CAGR under 50% of AVGO's 181.31%. Michael Burry would suspect a significant competitive gap or product weakness.
14.67%
3Y revenue/share CAGR under 50% of AVGO's 173.06%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
54.64%
10Y OCF/share CAGR under 50% of AVGO's 9254.87%. Michael Burry would worry about a persistent underperformance in cash creation.
22.90%
Below 50% of AVGO's 518.07%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
67.10%
3Y OCF/share CAGR at 50-75% of AVGO's 127.54%. Martin Whitman would suspect weaker recent execution or product competitiveness.
91.38%
Below 50% of AVGO's 4754.27%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
23.77%
Below 50% of AVGO's 176.78%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
116.01%
3Y net income/share CAGR 50-75% of AVGO's 167.85%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
37.06%
Equity/share CAGR of 37.06% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
7.25%
Below 50% of AVGO's 172.14%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-1.77%
Negative 3Y equity/share growth while AVGO is at 80.62%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
1156.44%
Dividend/share CAGR of 1156.44% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
190.22%
Below 50% of AVGO's 526.97%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
81.56%
3Y dividend/share CAGR at 50-75% of AVGO's 157.97%. Martin Whitman might see a weaker short-term approach to distributing cash.
8.93%
AR growth well above AVGO's 4.02%. Michael Burry fears inflated revenue or higher default risk in the near future.
6.74%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-3.35%
Negative asset growth while AVGO invests at 1.75%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.19%
We have a declining book value while AVGO shows 8.24%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.05%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
5.23%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
8.89%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.